ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-pxxvi.xmlOncology Research Program2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-pxxvi.pdf2026-04-18Oncology Research Programhttps://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-pxvi.xmlNCCN News2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-pxvi.pdf2026-04-18NCCN Newshttps://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1379.xmlCounterpoint: Adjuvant Therapy in Stage II Colon Cancer: Pain Not Justified by the Gain2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1379.pdf2026-04-18Counterpoint: Adjuvant Therapy in Stage II Colon Cancer: Pain Not Justified by the Gainhttps://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1323.xmlLung Cancer Screening: The Last 10 Years2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1323.pdf2026-04-18Lung Cancer Screening: The Last 10 Yearshttps://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1318.xmlThe Oncologist’s Impact on Drug Choices2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1318.pdf2026-04-18The Oncologist’s Impact on Drug Choiceshttps://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1315.xmlA “Shot Heard ’Round the World” on Cancer Drug Costs?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1315.pdf2026-04-18A “Shot Heard ’Round the World” on Cancer Drug Costs?https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1370.xmlPoint: Treating Stage II Colon Cancer: The Quest for Personalized Adjuvant Care2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1370.pdf2026-04-18Point: Treating Stage II Colon Cancer: The Quest for Personalized Adjuvant Carehttps://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1339.xmlOvarian Cancer, Version 3.20122026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1339.pdf2026-04-18Ovarian Cancer, Version 3.2012https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1355.xmlUpdate on Emerging Technologies in Breast Imaging2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1355.pdf2026-04-18Update on Emerging Technologies in Breast Imaginghttps://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1330.xmlSuccessful Resection After Neoadjuvant Therapy in Pancreatic Adenocarcinoma2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1330.pdf2026-04-18Successful Resection After Neoadjuvant Therapy in Pancreatic Adenocarcinomahttps://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1412.xmlPrevention and Treatment of Cancer-Related Infections2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1412.pdf2026-04-18Prevention and Treatment of Cancer-Related Infectionshttps://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1391.xmlA Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m2 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1391.pdf2026-04-18A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m2 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1447.xmlCurrent Issues in Vaccines for Adult Patients With Hematologic Malignancies2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1447.pdf2026-04-18Current Issues in Vaccines for Adult Patients With Hematologic Malignancieshttps://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1456.xmlBRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted Therapy2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1456.pdf2026-04-18BRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted Therapyhttps://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1403.xmlNew Agents in Metastatic Prostate Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/10/11/article-p1403.pdf2026-04-18New Agents in Metastatic Prostate Cancer